Strategic Research Programme: Cancer Cell Targeting in Myeloma and Melanoma (MyMe)

Thielemans, Kris (Administrative Promotor)
Vanderkerken, Karin (Co-Promotor)
Breckpot, Karine (Co-Promotor)

Description

Anti-tumor vaccination requires the identification of target antigens on resistant tumor subpopulations, adequate immune competence of the patients and the availability of efficient vaccination techniques.

Acronym	SRP48
Status	Active
Effective start/end date	1/11/17 → 31/10/22

Flemish discipline codes

Cancer therapy

Keywords

Dendritic Cells
Tonic Pain
Evoked Potentials
Bispecific Antibodies
Immunotherapy
Immunology
Oncology

1 Finished

SRP14: SRP (Zwaartepunt): Targeting residual cancer cells: myeloma and melanoma as model diseases
Thielemans, K. & Vanderkerken, K.
1/11/12 → 31/10/17
Project: Fundamental